DNA Methylation Patterns Predict MDS Treatment Response

Researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have identified specific DNA methylation patterns present at diagnosis that may help predict which patients with myelodysplastic syndromes (MDS) will respond to azacitidine. This key finding from a new multicenter study, published in the Journal of Clinical Investigation, suggests that the epigenetic landscape of the disease holds crucial clues for tailoring therapy. The study indicates that analyzing these chemical marks on DNA offers a more accurate predictive tool than measuring gene activity alone, potentially paving the way for more personalized care strategies for patients facing this complex group of bone marrow disorders.

For individuals diagnosed with MDS, a condition in which the bone marrow fails to produce healthy blood cells normally, selecting the most effective treatment remains a significant clinical challenge. The new research addresses this gap by examining biological features present at the time of diagnosis. By integrating DNA methylation data with gene expression, mutations, and clinical information, the research team developed a model designed to identify patients most likely to benefit from azacitidine, a primary therapy used for MDS. This approach aims to answer a critical question for patients and doctors: which treatment is most likely to work for a specific individual before therapy begins.

The study involved a comprehensive analysis of 98 patients with MDS, examining DNA mutations, chemical marks on DNA, and gene activity. The researchers grouped these patients based on their distinct DNA methylation patterns and developed computer models to predict their response to azacitidine. To ensure the robustness of their findings, the team tested these predictive models in an independent patient group. This rigorous design allowed the researchers to capture a fuller picture of the disease biology and understand which specific features could help distinguish between patients who respond to the treatment and those who do not. The focus on epigenetic changes, which alter gene activity without changing the underlying DNA sequence, provides a new lens for understanding the heterogeneity of MDS.

The analysis revealed seven distinct groups, or clusters, of patients characterized by unique biological features. One of these groups, referred to as Cluster VI, was notable for having relatively few DNA mutations.

A central finding of the study is that DNA methylation was more useful than gene activity alone for predicting treatment response. Furthermore, the researchers found that some of the strongest predictive signals originated from regulatory regions of the DNA, areas that have traditionally received less attention in cancer research.

Maria “Ken” Figueroa, M.D., a Sylvester researcher and co-lead of the study, emphasized the broader implications of these findings. She noted that the results provide a new perspective on why some patients benefit from treatment while others do not. This understanding opens an opportunity to think more broadly about how epigenetic information can be used to understand MDS and, eventually, to guide clinical care. Figueroa stated that the goal is to get closer to answering one of the most important questions for a patient at diagnosis: which treatment is most likely to work for them.

Mikkael Sekeres, M.D., M.S., chief and professor of hematology at Sylvester and co-lead of the study, described the work as a step in the right direction toward a major goal in cancer treatment: determining whether a therapy will work before it is even started. While he acknowledged that further research is needed before these findings can guide routine clinical care, Sekeres expressed optimism about the potential for more informed treatment decisions. He highlighted that while there is still more work ahead, studies like this provide the field with a reason to be hopeful. The ultimate aim, he said, is to turn a better understanding of MDS into better guidance for patients, allowing them to face treatment with greater confidence in the path ahead.

By demonstrating the predictive value of epigenetic markers, the research team has provided a potential path toward more personalized care.

Subject of Research: Predictive value of DNA methylation patterns for azacitidine response in myelodysplastic syndromes

Article Title: Sylvester researchers identify DNA marker that could predict treatment response in MDS

Article References: Sylvester researchers identify DNA marker that could predict treatment response in MDS. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: MDS, DNA methylation, azacitidine, epigenetics, Sylvester Comprehensive Cancer Center, personalized medicine, hematology, cancer research, Sylvester, researchers, identify, marker